Modifying cancer-related fatigue by optimizing sleep quality

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 1, 2008, Pages 3-13

  Berger, Ann Malone ^a,d   Mitchell, Sandra A ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer; Daytime sleepiness; Evidence based practice; Fatigue; Sleep disturbances; Symptom management

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; DONEPEZIL; HYPNOTIC AGENT; MELATONIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; PAROXETINE; VALERIAN;

BEHAVIOR THERAPY; CANCER FATIGUE; CANCER PATIENT; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; HUMAN; INSOMNIA; MOOD DISORDER; PARASOMNIA; QUALITY OF LIFE; REVIEW; SCREENING; SELF REPORT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP PATTERN; SLEEP THERAPY; SLEEP TIME; SLEEP WAKING CYCLE; TREATMENT OUTCOME;

EID: 38949124050     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0002     Document Type: Review

References (114)

1. Prue G, Rankin J, Allen J, et al. Cancer-related fatigue: a critical appraisal. Eur J Cancer 2006;42:846-863.
2. Mock V, Abernethy AP, Atkinson A, et al. NCCN Clinical Practice Guidelines in Oncology - Cancer-Related Fatigue, v.2.2007. Available at: http://www.nccn.org/. Accessed September 26, 2007.
3. Piper B. Fatigue. In: Carrieri-Kohlman V, Lindsey A, West C, eds. Pathophysiological Phenomena in Nursing, 3rd ed. St Louis, MO: Saunders; 2003:209-234.
4. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(Suppl 1):4-10.
5. Barsevick AM, Whitmer K, Nail LM, et al. Symptom cluster research: conceptual, design, measurement, and analysis issues. J Pain Symptom Manage 2006;31:85-95.
6. Davidson JR, MacLean AW, Brundage MD, et al. Sleep disturbance in cancer patients. Soc Sci Med 2002;54:1309-1321.
7. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001;19:895-908.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
9. Devine EB, Hakim Z, Green J. A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adults. Pharmacoeconomics 2005;23:889-912.
10. Lee KA, Ward TM. Critical components of a sleep assessment for clinical practice settings. Issues Ment Health Nurs 2005;26:739-750.
11. Savard MH, Savard J, Simard S, et al. Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology 2005;14:429-441.
12. Berger A, Parker K, Young-McCaughan S, et al. Sleep wake disturbances in people with cancer and their caregivers: state of the science. Oncol Nurs Forum 2005;32:E98-E126.
13. National Cancer Institute. Sleep Disorders (PDQ®) 02/16/2006. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/ sleepdisorders/healthprofessional/. Accessed September 26, 2007.
14. Buysse DJ, Ancoli-Israel S, Edinger JD, et al. Recommendations for a standard research assessment of insomnia. Sleep 2006;29:1155-1173.
15. Lee KA. Impaired sleep. In: Carrieri-Kohlman V, Lindsey A, West C, eds. Pathophysiological Phenomena in Nursing, 3rd ed. St. Louis, MO: Saunders; 2003:363-385.
16. Spielman AJ, Glovinsky P. A conceptual framework of insomnia for primary care practitioners: predisposing, precipitating and perpetuating factors. Sleep Medicine Alerts 2004;9:1-6.
17. Borbely AA, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms 1999;14:557-568.
18. Vena C, Parker K, Cunningham M, et al. Sleep-wake disturbances in people with cancer part I: an overview of sleep, sleep regulation, and effects of disease and treatment. Oncol Nurs Forum 2004;31:735-746.
19. Payne JK. A neuroendocrine-based regulatory fatigue model. Biol Res Nurs 2004;6:141-150.
20. Bower JE, Ganz PA, Dickerson SS, et al. Diurnal Cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005;30:92-100.
21. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-160.
22. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004;11:279-292.
23. Payne JK. A neuroendocrine-based regulatory fatigue model. Biol Res Nurs 2004;6:141-150.
24. Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007;21:863-871.
25. Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007;12(Suppl 1):22-34.
26. Wood LJ, Nail LM, Gilster A, et al. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 2006;33:535-542.
27. Berger AM, Sankaranarayanan J, Watanabe-Galloway S. Current methodological approaches to the study of sleep disturbances and quality of life in adults with cancer: a systematic review. Psychooncology 2007;16:401-420.
28. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic & Coding Manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
29. Carpenter JS, Elam JL, Ridner SH, et al. Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncol Nurs Forum 2004;31:591-598.
30. NIH. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-1057.
31. Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J 2006;12:432-443.
32. Bardwell WA, Profant J, Casden DR, et al. The relative importance of specific risk factors for insomnia in women treated for early-stage breast cancer. Psychooncology 2007; epub ahead of print.
33. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
34. Ancoli-Israel S. Sleep and fatigue in cancer patients. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: Saunders; 2005:1218-1224.
35. Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. Oncologist 2007:12(Suppl 1):35-42.
36. Barton-Burke M. Cancer-related fatigue and sleep disturbances. Cancer Nurs 2006;29;2(Suppl 2):72-77.
37. de Jong N, Courtens AM, Abu-Saad HH, et al. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs 2002;25:283-297; quiz 298-289.
38. Donovan KA, Jacobsen PB. Fatigue, depression, and insomnia: evidence for a symptom cluster in cancer. Semin Oncol Nurs 2007;23:127-135.
39. Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev 2006;10:419-429.
40. Lee K, Cho M, Miaskowski C, et al. Impaired sleep and rhythms in persons with cancer. Sleep Med Rev 2004;8:199-212.
41. Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone 2004;6(Suppl 1D) :S15-21.
42. Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and Orcadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006;14:201-209.
43. Berger AM, Farr LA, Kuhn BR, et al. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage 2007;33:398-409.
44. Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999;18:233-242.
45. Berger AM, Farr L. The influence of daytime inactivity and night-time restlessness on cancer-related fatigue. Oncol Nurs Forum 1999;26:1663-1671.
46. Kuo HH, Chiu MJ, Liao WC, et al. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc 2006;105:64-69.
47. Barton-Burke M. Cancer-related fatigue and sleep disturbances. Further research on the prevalence of these two symptoms in long-term cancer survivors can inform education, policy, and clinical practice. Am J Nurs 2006;106(Suppl 3):72-77.
48. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743-753.
49. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998;16:1689-1696.
50. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 2002;38:27-43.
51. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
52. Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 1999;17:320-332.
53. Mystakidou K, Parpa E, Tsilika E, et al. Sleep quality in advanced cancer patients. J Psychosom Res 2007;62:527-533.
54. Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 1998;25:51-62.
55. Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum 2000;27:1443-1448.
56. Roscoe JA, Morrow GR, Hickok JT, et al, Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002;10:329-336.
57. Levin RD, Daehler MA, Grutsch JF, et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 2005;93:1202-1208.
58. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum Cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:1757-1764.
59. Glaus A, Boehme CH, Thürlimann B, et al. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 1006;17:801-806.
60. Given B, Given C, Azzouz F, et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 2001;50:222-232.
61. Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 2007;39:61-67.
62. Barsevick AM, Dudley WN, Beck SL. Cancer-related fatigue, depressive symptoms, and functional status: a mediation model. Nurs Res 2006;55:366-372.
63. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006;29:1398-1414.
64. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 2006;29:1415-1419.
65. Sackett DL. Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol 1993;9:487-489.
66. Barton S, ed. Clinical Evidence Concise: The International Source of the Best Available Evidence for Effective Health Care, 7th ed. Kingsport, TN: BMJ Publishing Group; 2002.
67. Mitchell SA, Friese CR. Weight of evidence. Available at: http://www.ons.org/outcomes/tables/documents/woevidence.pdf. Accessed September 26, 2007.
68. Gobel BH, Beck SL, O'Leary C. Nursing-sensitive patient outcomes: the development of the putting evidence into practice resources for nursing practice. Clin J Oncol Nurs 2006;10:621-624.
69. Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99-113.
70. Page MS, Berger AM, Johnson LB. Putting evidence into practice: evidence-based interventions for sleep-wake disturbances. Clin J Oncol Nurs 2006;10:753-767.
71. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172-1180.
72. Belanger L, Savard J, Morin CM. Clinical management of insomnia using cognitive therapy. Behav Sleep Med 2006;4:179-198.
73. Szuba MP, Kloss JE, Dinges DF. Insomnia Principles and Management. New York: Cambridge University Press; 2003.
74. Currie SR, Wilson KG, Pontefract AJ, et al. Cognitive-behavioral treatment of insomnia secondary to chronic pain. J Consult Clin Psycho 2000;68:407-416.
75. Lichstein KL, Wilson NM, Johnson CT. Psychological treatment of secondary insomnia. Psychol Aging 2000;15:232-240.
76. Currie SR, Clark S, Hodgins DC, et al. Randomized controlled trial of brief cognitive-behavioural interventions for insomnia in recovering alcoholics. Addiction 2004;99:1121-1132.
77. Rybarczyk B, Lopez M, Benson R, et al. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging 2002;17:288-298.
78. Berger AM, VonEssen S, Kuhn BR, et al. Feasibility of a sleep intervention during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 2002;29:1431-1441.
79. Berger AM, Von Essen S, Kuhn BR, et al. Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: results of a feasibility intervention study. Oncol Nurs Forum 2003;30:513-522.
80. Davidson JR, Waisberg JL, Brundage MD, et al. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology 2001;10:389-397.
81. Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003;71:189-200.
82. Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005;23:6083-6096.
83. Carlson LE, Garland SN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. Int J Behav Med 2005;12:278-285.
84. Kim Y, Roscoe JA, Morrow GR. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. Support Care Cancer 2002;10:416-421.
85. Mock V, Dow KH, Meares CJ, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997;24:991-1000.
86. Culpepper L. Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin 2006;22:1257-1268.
87. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev 2004;4:CD003346.
88. Taibi DM, Landis CA, Perry H, et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007;11:209-230.
89. Bain KT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 2006;4:168-192.
90. Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 2007;21: 389-405.
91. Dundar Y, Dodd S, Strobl J, et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 2004;19:305-322.
92. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-1173.
93. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003;21:4439-4443.
94. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003;26:1049-1054.
95. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:2073-2078.
96. Cullum JL, Wojciechowski AE, Pelletier G, et al. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49:139-144.
97. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006;14:210-215.
98. Moss EL, Simpson JS, Pelletier G, et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006;15:259-267.
99. Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001;18:187-192.
100. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;29:E85-E90.
101. Shaw EG, Rosdhal R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006;24:1415-1420.
102. Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002;16:261-263.
103. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-652.
104. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-1641.
105. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemothetapy. Breast Cancer Res Treat 2005;89:243-249.
106. Weitzner MA, Moncello J, Jacobsen PB, et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337-345.
107. Caraceni A, Simonetti F. Psychostimulants: new concepts for palliative care from the modafinil experience? J Pain Symptom Manage 2004;28:97-99.
108. Cox JM, Pappagallo M. Modafinil: a gift to portmanteau. Am J Hosp Palliat Care 2001;18:408-410.
109. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130-136.
110. Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj 2005;19:725-727.
111. Spathis A, Morrish E, Booth S, et al. Selective circadian rhythm disturbance in cerebral lymphoma. Sleep Med 2003;4:583-586.
112. Torta R, Berra C, Binaschi L, et al. Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. Support Care Cancer 2007;15:539-546.
113. Food and Drug Administration. (March 14, 2007). FDA News, March 14, 2007. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html. Accessed September 26, 2007.
114. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20:533-559.